According to our (Global Info Research) latest study, the global Equine Immunoglobulin and F(ab')2 Products market size was valued at US$ 1484 million in 2025 and is forecast to a readjusted size of US$ 1971 million by 2032 with a CAGR of 4.1% during review period.
Equine Immunoglobulin and F(ab')2 Fragment Products refer to a class of passive immunotherapy biologics derived from hyperimmune horse plasma obtained after immunization with venoms, bacterial toxins, viral antigens, or related immunogens, followed by purification, enzymatic digestion, viral inactivation, formulation, and sterile filling. Major commercial products include snake antivenoms, equine tetanus immunoglobulin, equine rabies immunoglobulin, and selected antitoxin preparations. Upstream raw materials and inputs mainly include immunized horses, venoms or toxoids/antigens, plasma collection and fractionation materials, enzymes, purification reagents, stabilizers, packaging materials, and cold-chain logistics, while downstream customers are primarily hospital emergency departments, trauma treatment centers, envenomation treatment institutions, public health agencies, and government stockpile systems. The global production capacity for equine immunoglobulin and F(ab')2 products is estimated at approximately 19.4 million vials in 2025, with sales volume of about 15.68 million vials, an average ex-factory price of around US$92 per vial, and gross margins generally in the range of 45%–72%. Overall, this market is characterized by strong regionalization and indication-specific segmentation: developing markets are dominated by high-volume, lower-priced demand, whereas developed markets are more strongly driven by specialized clinical use and public health stockpiling, resulting in higher value-added product demand.
This report is a detailed and comprehensive analysis for global Equine Immunoglobulin and F(ab')2 Products market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Equine Immunoglobulin and F(ab')2 Products market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Equine Immunoglobulin and F(ab')2 Products market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Equine Immunoglobulin and F(ab')2 Products
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Equine Immunoglobulin and F(ab')2 Products market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Laboratorios Silanes, Emergent BioSolutions, Shanghai Serum Bio-Technology, VINS Bioproducts, Bharat Serums and Vaccines, KM Biologics, Inosan Biopharma, MicroPharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Equine Immunoglobulin and F(ab')2 Products market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tetanus Antitoxins
Snake Antivenoms
Anti-rabies Sera
Other
Market segment by Sales Channels
Online Sales
Offline Sales
Market segment by Application
Hospital
Clinic
Others
Major players covered
Laboratorios Silanes
Emergent BioSolutions
Shanghai Serum Bio-Technology
VINS Bioproducts
Bharat Serums and Vaccines
KM Biologics
Inosan Biopharma
MicroPharm
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Equine Immunoglobulin and F(ab')2 Products product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Equine Immunoglobulin and F(ab')2 Products, with price, sales quantity, revenue, and global market share of Equine Immunoglobulin and F(ab')2 Products from 2021 to 2026.
Chapter 3, the Equine Immunoglobulin and F(ab')2 Products competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Equine Immunoglobulin and F(ab')2 Products breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Equine Immunoglobulin and F(ab')2 Products market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Equine Immunoglobulin and F(ab')2 Products.
Chapter 14 and 15, to describe Equine Immunoglobulin and F(ab')2 Products sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Equine Immunoglobulin and F(ab')2 Products. Industry analysis & Market Report on Equine Immunoglobulin and F(ab')2 Products is a syndicated market report, published as Global Equine Immunoglobulin and F(ab')2 Products Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Equine Immunoglobulin and F(ab')2 Products market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.